Recruiting Lung Cancer Studies in Hangzhou
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with p...
Volrustomig Priming Regimens Exploratory Phase II Platform Study
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with spe...
About Lung Cancer Clinical Trials in Hangzhou
Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.
There are currently 2 lung cancer clinical trials recruiting participants in Hangzhou, ZHEJIANG. These studies are seeking a combined 866 participants. Research is being sponsored by Daiichi Sankyo, AstraZeneca. Clinical trial participation is free and participants receive study-related medical care at no cost.
Lung Cancer Clinical Trials in Hangzhou — FAQ
Are there lung cancer clinical trials in Hangzhou?
Yes, there are 2 lung cancer clinical trials currently recruiting in Hangzhou, ZHEJIANG. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Hangzhou?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Hangzhou research site will contact you about next steps.
Are clinical trials in Hangzhou free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Hangzhou studies also compensate for your time and travel.
What lung cancer treatments are being tested?
The 2 active trials in Hangzhou are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.
Data updated March 2, 2026 from ClinicalTrials.gov